Replies to post #219417 on Biotech Values

[DewDiligence]

MRK has three strong growth engines: Keytruda, vaccines, and animal health; the latter has been largely overlooked by Wall Street but is now large enough to require its own segment reporting.

Inasmuch as demand for pet care and protein foods rises in step with increasing global affluence, it’s not surprising that MRK’s animal-health business is growing rapidly in emerging markets. If you ascribe a ZTS-like valuation to this business segment, MRK’s overall valuation is not hard to justify, IMO.

In the institutional portfolio I manage, I bought some MRK a month ago in the high 50s.

[dewophile]

I'm sitting on some cash and also thinking where to put it. If keytruda is indeed a 10 billion drug it should be a buy. however there is just so much competition in this space that who knows how long that will last.
I am also looking at REGN but having he same dilemma. What kind of competition will Eylea start to face from the roche/novartis drug in development.
Every other REGN drug is also in a competitive space, but I do think dupilumab could be differentiated and end up a real winner